title: [Low doses of subcutaneous cytosine arabinoside in the treatment of patients with myelodysplastic syndromes].
authors.forename: A
authors.initials: A
authors.lastname: Avilés
authors.forename: F
authors.initials: F
authors.lastname: Tripp
authors.forename: A
authors.initials: A
authors.lastname: Velásquez
authors.forename: M E
authors.initials: ME
authors.lastname: Rubio
authors.forename: J
authors.initials: J
authors.lastname: González-Llavén
mesh_terms: D000741:Anemia, Aplastic / Q000139:chemically induced; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007239:Infections / Q000209:etiology; D007279:Injections, Subcutaneous; D007951:Leukemia, Myeloid / Q000188:drug therapy*
chemical_list: D003561:Cytarabine
vernacular_title: Dosis bajas de arabinósido de citosina subcutáneo en el tratamiento de pacientes con síndromes mielodisplásicos.